First Trust Advisors LP Has $147.06 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

First Trust Advisors LP reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 230,187 shares of the company’s stock after selling 24,366 shares during the period. First Trust Advisors LP owned 0.29% of IDEXX Laboratories worth $147,064,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its stake in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after buying an additional 605,290 shares during the period. Generation Investment Management LLP bought a new position in IDEXX Laboratories during the second quarter worth about $304,277,000. Norges Bank acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $221,955,000. JPMorgan Chase & Co. grew its position in shares of IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after buying an additional 326,348 shares during the period. Finally, Schroder Investment Management Group increased its stake in shares of IDEXX Laboratories by 295.1% in the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after acquiring an additional 235,863 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

IDXX has been the topic of a number of analyst reports. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. UBS Group cut their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, Barclays reduced their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Down 1.7%

NASDAQ IDXX opened at $608.41 on Monday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market cap of $48.44 billion, a P/E ratio of 46.55, a P/E/G ratio of 3.69 and a beta of 1.66. The stock’s 50-day moving average is $666.94 and its 200-day moving average is $668.62.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm posted $2.53 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.